These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 22415131)

  • 1. Environmental cues to urgency and leakage episodes in patients with overactive bladder syndrome: a pilot study.
    Victor E; O'Connell KA; Blaivas JG
    J Wound Ostomy Continence Nurs; 2012; 39(2):181-6. PubMed ID: 22415131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cues to urinary urgency and urge incontinence: how those diagnosed with overactive bladder syndrome differ from undiagnosed persons.
    OʼConnell KA; Torstrick A; Victor E
    J Wound Ostomy Continence Nurs; 2014; 41(3):259-67. PubMed ID: 24805178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulus-associated urinary urges in overactive bladder syndrome.
    O'Connell KA; Singer J; Rajan S
    Neurourol Urodyn; 2018 Jan; 37(1):284-290. PubMed ID: 28464244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the elements of overactive bladder: questions raised by the EPIC study.
    Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
    BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating patients' symptoms of overactive bladder by questionnaire: the role of urgency in urinary frequency.
    Mitchell SA; Brucker BM; Kaefer D; Aponte M; Rosenblum N; Kelly C; Hickling D; Nitti VW
    Urology; 2014 Nov; 84(5):1039-43. PubMed ID: 25443897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and effect on health-related quality of life of overactive bladder in older americans: results from the epidemiology of lower urinary tract symptoms study.
    Sexton CC; Coyne KS; Thompson C; Bavendam T; Chen CI; Markland A
    J Am Geriatr Soc; 2011 Aug; 59(8):1465-70. PubMed ID: 21718275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between psychological stress levels and the severity of overactive bladder symptoms.
    Lai H; Gardner V; Vetter J; Andriole GL
    BMC Urol; 2015 Mar; 15():14. PubMed ID: 25887525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS.
    Milsom I; Kaplan SA; Coyne KS; Sexton CC; Kopp ZS
    Urology; 2012 Jul; 80(1):90-6. PubMed ID: 22748867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevalence of clinically meaningful overactive bladder: bother and quality of life results from the population-based FINNO study.
    Vaughan CP; Johnson TM; Ala-Lipasti MA; Cartwright R; Tammela TL; Taari K; Auvinen A; Tikkinen KA
    Eur Urol; 2011 Apr; 59(4):629-36. PubMed ID: 21306820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining overactive bladder as hypersensitivity.
    Yamaguchi O; Honda K; Nomiya M; Shishido K; Kakizaki H; Tanaka H; Yamanishi T; Homma Y; Takeda M; Araki I; Obara K; Nishizawa O; Igawa Y; Goto M; Yokoyama O; Seki N; Takei M; Yoshida M
    Neurourol Urodyn; 2007 Oct; 26(6 Suppl):904-7. PubMed ID: 17663416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
    Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
    Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National community prevalence of overactive bladder in the United States stratified by sex and age.
    Coyne KS; Sexton CC; Vats V; Thompson C; Kopp ZS; Milsom I
    Urology; 2011 May; 77(5):1081-7. PubMed ID: 21256571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.